Clinical Trials Transformation Initiative (CTTI)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2007
  • Initiating Organization: Duke University
  • Initiator Type: Academia
  • No disease focus
  • Location: North America
CTTI

Abstract

The U.S. Food and Drug Administration (FDA) and Duke University co-founded the Clinical Trials Transformation Initiative (CTTI) to identify and promote practices that will increase the quality and efficiency of clinical trials. Their evidence-based work is being used to inform both policy and decision-making in the interest of public health, as well as to streamline the operation of clinical trials. CTTI engages all stakeholders as equal partners to analyze existing research impediments and recommend consensus-driven, actionable solutions that will lead to a more sustainable and effective clinical trial system.

Mission

CTTI’s mission is to identify and promote practices that will increase the quality and efficiency of clinical trials. Its vision is a high-quality clinical trial system that is patient-centered and efficient, enabling reliable and timely access to evidence-based prevention and treatment options.

Core Values:

  • Act in the interest of the public’s health to improve the clinical trial enterprise
  • Hold paramount the need to protect human subjects and their privacy
  • Encourage the input and participation of all stakeholders (e.g., academia, industry, investigators, patients, and regulators) to move the system forward
  • Work to identify and manage conflict of interest and bias to avoid undue influence of any individual, organization, or sector
  • Hold that, to the extent possible, recommendations for change should be scientifically derived
  • Activities and innovations deriving from CTTI will be rapidly communicated to interested parties and the public
  • The integrity and transparency of CTTI, as a collaborative organization, is of utmost importance

CTTI projects are organized into five categories: AB (Antibacterial) Drug Development, Investigational Plan, Study Start-Up, Study Conduct, and Analysis and Dissemination. 

AB Drug Development was created in response to growing rates of bacterial resistance and slowing development of new antibacterials, creating an urgent need for treatment options for patients infected by resistant bacteria.  

The Investigational Plan describes the essential background documentation related to the test article, protocol creation, and all operational aspects of a study. It also includes how ethical and regulatory considerations will be managed during the course of the study. The CTTI projects that fall under this category focus on innovating this preparatory phase of the clinical trial process.

Study Start-Up includes all of the activities associated with identifying, qualifying, and activating investigational sites. The CTTI projects that fall under this category are concerned with site-level regulatory approvals and site preparation for successful enrollment.

Study Conduct describes the active data collection phase of an investigation in which patients, sites, and sponsors interact to test the safety and/or efficacy of the investigational article. The CTTI projects that fall under this category are concerned with (a) protocol adherence issues, (b) patient follow-up and safety, and (c) monitoring and transfer of safety data between sites and sponsor.

Analysis and Dissemination addresses the phase of an investigation in which data are cleaned and analyzed, then presented and published in the public domain. The CTTI projects that fall under this category analyze data output from clinical trial research, identify areas of improvement, and focus on the dissemination of clinical trial results to the scientific community and public.

Structure & Governance

An Executive Committee sets the overall direction and strategy for the initiative and oversees the use of annual membership fees. A Steering Committee, consisting of representatives from CTTI members across multiple sectors, provides input into decisions about CTTI priorities, projects, and recommendations. CTTI members also play an important role in facilitating improvements in the design and conduct of clinical trials within their organizations and the overall enterprise. A central staff supports the development and execution of projects and dissemination of project results. In addition, staff members organize and support activities of the Executive and Steering Committees.

Financing

CTTI receives financial and in-kind support from many groups committed to improving clinical trials.

Duke University, as the host of CTTI, received a cooperative agreement (U19 FD003800) from FDA, followed by a grant (R18 FD005292), which provides some support for all current projects. Member organizations pay an annual fee, which supports CTTI infrastructure expenses and projects.

In addition, individuals from many member organizations, and some nonmember organizations, contribute time and other resources to make CTTI projects successful.

CTTI encourages the use of all materials listed on its website in the pursuit of improving the clinical trials enterprise. Its recommendations, tools, meeting summaries, and more are available to the public for free.

Impact/Accomplishment

CTTI has published recommendations and articles on clinical trials that are highly regarded and used by many stakeholders in the clinical trial process. From 2011 to 2015, CTTI published 26 papers on its projects and progress. It has contributed greatly to innovative trial design including working to establish centralized institutional review boards (IRBs) for multicenter trials. FDA participation in CTTI has allowed the agency to learn from partners and stakeholders and to begin to implement new recommendations for clinical trials so that efficient trials with flexible designs aided by innovative technologies are no longer the exception to the rule.

CTTI hosts expert meetings where a diverse cross-section of stakeholders from the clinical trial enterprise can tackle existing challenges and collaborate to find innovative solutions. Upon completing an expert meeting, CTTI aims to share the discussions with a wider audience and promotes adoption of novel approaches to existing issues in the clinical trials enterprise.

CTTI’s tools are created to facilitate the adoption of official recommendations and are available on its website. These recommendations are based on evidence generated by engaging all stakeholders involved in the clinical trial process.

Points of Contact

300 W. Morgan St
Suite 800
Durham, NC 27701-2183
phone: 919-668-3437
email: ctti@mc.duke.edu

Sponsors & Partners

ACI Clinical

Amgen

AstraZeneca

Bard

Bristol-Myers Squibb (BMS)

Celegene

Cempra

EMD Serono

Genetech

GlaxoSmithKline (GSK)

Johnson and Johnson

Lilly

Medtronic

Merck

Pfizer

Purdue

St. Jude Medical

Target Health, Inc.

The Medicines Company

Office for Human Research Protections (OHRP)

Department of Veterans Affairs

Agency for Healthcare Research and Quality (AHRQ)

Centers for Disease Control and Prevention (CDC)

Centers for Medicare & Medicaid Services (CMS)

U.S. Food and Drug Administration (FDA)

National Institutes of Health (NIH)

Clinical Data Interchange Standards Consortium (CDISC)

Chesapeake IRB

American College of Radiation Oncology (ACRO)

 

Association of Clinical Research Professionals (ACRP)

AdvaMed

Bio

Biomedical Research Alliance of New York (BRANY)

MedStar Health Research Institute

Palo Alto Investors

Consortium of Independent Review Boards (CIRB)

CITI Program

DIA

Greenleaf Health LLC

King & Spalding

Melanoma Research Alliance

The Michael J Fox Foundation for Parkinson’s Research

PMG Research

Quorum Review IRB

Society for Clinical Trials

Society for Clinical Research Sites (SCRS)

WCG

Susan G. Komen

NYU Langone Medical Center

Alliance for Lupus Research

Foundation for Prader-Wili Research

Friends of Cancer Research

Juvenile Diabetes Research Foundation (JDRF)

The Life Raft Group

University of Kansas (KU) Medical Center

UW Health

MPN Research Foundation

NORD

Parent Project Muscular Dystrophy

Parkinson’s Disease Foundation

Pulmonary Fibrosis Foundation

The University of Sydney

 

C5 Research

Dana-Farber Cancer Institute

Duke Medicine

The Feinstein Institute for Medical Research

The George Institute for Global Health

 

 

Population Health Research Institute (PHRI)

University of Missouri Health System, School of Medicine

University of North Carolina (UNC) Healthcare

University of Oxford

University of Rochester Medical Center

 

 


Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.